Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody

NCT04563923 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Nice as lead sponsor.

NCT NCT04563923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04563923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody
Lead sponsor
Centre Hospitalier Universitaire de Nice
Phase
Phase 2
Overall status
Completed
Start date
October 10, 2020
Completion date
March 31, 2024
Enrollment
15 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bullous pemphigoid